Wockhardt, a leading pharmaceutical and biotechnology major, announced that its Chicago-based arm Morton Grove Pharmaceuticals has got sanction from US Food and Drug Administration (USFDA) for selling an oral suspension of a combination of Amoxycillin and Clavulanate Potassium.

According to the sources, the said drug is indicated for the treatment of several common infections, especially in children. The product is marketed in the US by Glaxo SmithKline under the brand name Augmentin 250.

While commenting on the occasion, Mr. Habil Khorakiwal, chairman of Wockhardt stated, “Wockhardt is the first company to receive an Abbreviated New Drug Application (ANDA) approval for this strength of Augmentin.”

The sources further revealed that the product was developed as a part of a series of collaborative projects along with Cipla, another pharmaceutical major from India and would be exclusively manufactured and supplied for Wockhardt by Cipla from its FDA sanctioned facility in Goa, India.

Shares of Wockhardt gained Rs 3.3, or 3.46%, to settle at Rs 99 on Bombay Stock Exchange (BSE). The total volume of shares traded was 24,033 at the BSE.